Graeme Currie - Pasithea Therapeutics Chief Officer
| KTTAW Stock | USD 0.02 0.0003 1.50% |
Executive
Graeme Currie is Chief Officer of Pasithea Therapeutics Corp
| Age | 57 |
| Address | 1111 Lincoln Road, Miami Beach, FL, United States, 33139 |
| Phone | 702 514 4174 |
| Web | https://www.pasithea.com |
Graeme Currie Latest Insider Activity
Tracking and analyzing the buying and selling activities of Graeme Currie against Pasithea Therapeutics stock is an integral part of due diligence when investing in Pasithea Therapeutics. Graeme Currie insider activity provides valuable insight into whether Pasithea Therapeutics is net buyers or sellers over its current business cycle. Note, Pasithea Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Pasithea Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Graeme Currie over six months ago Acquisition by Graeme Currie of 5938 shares of Pasithea Therapeutics at 8.34 subject to Rule 16b-3 |
Pasithea Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.379) % which means that it has lost $0.379 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6325) %, meaning that it generated substantial loss on money invested by shareholders. Pasithea Therapeutics' management efficiency ratios could be used to measure how well Pasithea Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to -0.9 in 2024. Return On Capital Employed is likely to drop to -0.71 in 2024. At this time, Pasithea Therapeutics' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to climb to about 464.2 K in 2024, despite the fact that Non Currrent Assets Other are likely to grow to (8.7 B).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Emily Pimblett | Eliem Therapeutics | 40 | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| David Ege | Seres Therapeutics | 49 | |
| Nishi MD | Eliem Therapeutics | N/A | |
| JD Esq | Seres Therapeutics | 69 | |
| Alpa Parikh | Lumos Pharma | N/A | |
| MD FAAP | Lumos Pharma | N/A | |
| Matthew Henn | Seres Therapeutics | 49 | |
| Lisa MD | Seres Therapeutics | 65 | |
| Steve Parsons | Scpharmaceuticals | N/A | |
| Jeffrey Nelson | Milestone Pharmaceuticals | 43 | |
| MD MBA | Eliem Therapeutics | 50 | |
| John PharmD | Scpharmaceuticals | N/A | |
| Carlo Tanzi | Seres Therapeutics | N/A | |
| Kim Fox | Milestone Pharmaceuticals | N/A | |
| Nicole Esq | HCW Biologics | N/A | |
| Caroline Holda | Seres Therapeutics | N/A | |
| Rachael Nokes | Scpharmaceuticals | 49 | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| RPh Young | Seres Therapeutics | 57 | |
| Michael Hassman | Scpharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.38 |
Pasithea Therapeutics Leadership Team
Elected by the shareholders, the Pasithea Therapeutics' board of directors comprises two types of representatives: Pasithea Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pasithea. The board's role is to monitor Pasithea Therapeutics' management team and ensure that shareholders' interests are well served. Pasithea Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pasithea Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yassine Bendiabdallah, COO Clinics | ||
| Stanley Gloss, Chief Officer | ||
| MD BA, Ex CoFounder | ||
| Tiago Marques, CEO Director | ||
| Tiago MD, CEO Director | ||
| Daniel Schneiderman, Chief Officer | ||
| Graeme Currie, Chief Officer | ||
| BA MD, Executive CoFounder |
Pasithea Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pasithea Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Pasithea Stock Analysis
When running Pasithea Therapeutics' price analysis, check to measure Pasithea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pasithea Therapeutics is operating at the current time. Most of Pasithea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pasithea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pasithea Therapeutics' price. Additionally, you may evaluate how the addition of Pasithea Therapeutics to your portfolios can decrease your overall portfolio volatility.